Mode
Text Size
Log in / Sign up
Phase 2 Completed N=51 Randomized Single-blind Treatment

Dual-task Augmented Reality Treatment for Parkinson's Disease

Source: ClinicalTrials.gov NCT04634331 ↗
Enrolled (actual)
51
Serious AEs
2.0%
Results posted
Sep 2024
Primary outcomePrimary: Gait Velocity — 1.20; 1.22; 1.03; 1.07 meters/second

Summary

Activities of daily living (ADL) frequently involve the simultaneous performance of two or more tasks, such as crossing the street while holding a conversation, commonly referred to as dual tasking. The simultaneous performance of a motor and a cognitive task increases postural instability, gait dysfunction, and may increase fall rates in Parkinson's disease (PD). The goal of this project is to evaluate the effectiveness of utilizing a digital therapeutic, Dual-task Augmented Reality Treatment (DART) protocol, for the treatment of postural instability and gait dysfunction (PIGD) in individuals with PD. A randomized controlled trial will be conducted at the Main Campus of the Cleveland Clinic (Cleveland, OH). A total of 50 individuals with Parkinson's disease will be randomized into 1) a traditional multi-modal training group, or 2) multi-modal training administered via an augmented reality headset. Multi-modal therapy is where the participant practices performing two things at once (i.e. marching while answering math questions). Augmented reality is a type of head-worn technology that allows the individual to see the real world and places holograms in the space. Both groups will exercise 2x/week for a total of 8 weeks. Assessments involving walking, balancing, and turning will be completed to assess the efficacy of the treatment.

Outcome Measures

OutcomeResultp-value
PRIMARY
Gait Velocity
1.20; 1.22; 1.03; 1.07; 1.05; 1.09
PRIMARY
MDS-UPDRS III Score
34.1; 37.6; 34.9; 36.6
PRIMARY
Fall Frequency
0.5; 0.68; 0.64; 0.52

Eligibility Criteria

Inclusion Criteria

  • Adult with a diagnosis of idiopathic PD
  • Self-reported gait or balance deficits
  • Hoehn and Yahr stage I-III
  • Ability to ambulate >10 minutes continuously

Exclusion Criteria

  • Diagnosis of dementia or any neurocognitive impairment that compromises the ability to provide informed consent
  • >2 errors on the Short Portable Mental Status Questionnaire
  • Implanted deep brain stimulation electrodes
  • Musculoskeletal or cardiopulmonary issue that limits one's ability to engage in exercise
  • Neurological disease other than Parkinson's disease that impacts motor or cognitive function
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04634331). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search